

Fig.: 1




Fig.: 2




Fig.: 3




Fig.: 4




Fig.: 5




Fig.: 6




Fig.: 7




Fig.: 8




Fig.: 9




Fig.: 10




Fig.: 11




Fig.: 12




Fig.: 13




Fig.: 14




Fig.: 15




Fig.: 16




Fig.: 17




Fig.: 18




Fig.: 19




Fig.: 20




Fig.: 21




Fig.: 22




Fig.: 23




Figure 23 shows the normalized absorption spectra of two streptavidin conjugates obtained by reacting DY-631-NHS esters or DY-630-NHS esters with streptavidin in the molar ratio of 2:1. The advantage of the new markers is very clearly apparent from the clearly reduced aggregation band for the DY-631 conjugate at 580 nm.

Fig.: 24




Figure 24 shows the normalized absorption spectra of two streptavidin conjugates obtained by reacting DY-701-NHS esters or DY-700-NHS esters with streptavidine in the molar ratio of 2:1. The advantage of the new markers is very clearly apparent from the reduced aggregation band for the DY-701 conjugate at 650 nm.